This study looks at different ways of giving the drug zanubrutinib to older patients with mantle cell lymphoma (MCL), a type of cancer. Patients will also receive rituximab, a medicine that helps stop cancer from growing. The research checks if it's better to take zanubrutinib all the time or to take breaks in treatment after patients get better. This is called continuous vs. intermittent treatment. People in the study will be given zanubrutinib by mouth and rituximab through a vein. They will have tests like CT or PET scans, which are special pictures of the inside of the body.

• The study lasts up to 10 years with check-ups every 6 months after treatment ends.
• Participants may have extra blood tests and scans during the study.
• Eligibility requires specific health criteria and age limits.

Before joining, make sure you can commit to the long follow-up and are comfortable with the study requirements. Discuss any concerns with your doctor to ensure your health needs are met and understand potential risks and benefits.